4564 — OncoTherapy Science Cashflow Statement
0.000.00%
- ¥7bn
- ¥5bn
- ¥750m
Annual cashflow statement for OncoTherapy Science, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1,560 | -2,570 | -1,116 | -1,286 | -813 |
| Depreciation | |||||
| Non-Cash Items | -79.3 | 538 | 30.8 | 167 | 17.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -172 | -57.4 | 291 | -109 | -19.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1,763 | -2,073 | -795 | -1,228 | -815 |
| Capital Expenditures | -43.9 | -457 | -5.39 | -2.63 | -0.279 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -8.31 | -11 | -14.9 | -30.7 | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -52.2 | -468 | -20.3 | -33.4 | -0.279 |
| Financing Cash Flow Items | — | 12.3 | 96 | -11.2 | -51.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | — | 1,479 | 96 | 671 | 1,122 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1,815 | -1,062 | -719 | -590 | 306 |